NeuroMetrix gets FDA approval to market its Sensus pain-management device in the US
NeuroMetrix Inc., a medical device company based in Waltham, said its Sensus pain management device has been approved by the Food and Drug Administration.
In a press release, the company added that it now hopes that the device should reach the US market before the end of the year.
The Sensus is a non-invasive electrical nerve stimulator that is designed to provide relief from chronic pain.
People likely to benefit from the device are diabetics with a nerve-related complicationion called diabetic neuropathy. In many cases, these diabetics now use medication to manage pain. The hope is that the Sensus could eliminate or reduce their need for pain-management drugs.
Diabetic neuropathies affect more than 50 percent of diabetics, and the annual cost of diabetic neuropathies has been estimated at $14 billion in the United States, NeuroMetrix said.
The Sensus is designed to be worn around a patient’s upper calf, and pain relief is initiated by pressing a button that causes electrical stimulation of the nerves. The physiological principle is that excitation of normal nerves reduces transmission of pain signals to the brain, the company said.Chris Reidy can be reached at firstname.lastname@example.org.